Social Activity, Loneliness and Stigma During COVID-19 Outbreak

February 1, 2021 updated by: Linda Valeri, Columbia University

COVID-19 and Its Implications on Social Activity, Loneliness and Stigma

The overall goal of this study is to evaluate the association of quarantine measures for COVID-19 and perceived anxiety, stigma and loneliness and to evaluate the efficacy of interventions in reducing anxiety, loneliness and perception of stigma induced by self-isolation during the outbreak.

Specific Aims:

In the proposed study, participants will include members of the United States general population who will be randomly assigned to either (a) a vignette to learn about the COVID-19 outbreak, (b) a vignette to learn about the COVID-19 outbreak AND a video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends, (c) a vignette to learn about the COVID-19 outbreak AND a video aimed at sensitizing participants to COVID-19 related stigma, (d) Control arm. Web-based self-report questionnaires will be conducted to compare interventions and control groups. The short and low-cost online module will allow recruitment of a large sample of people.

Hypotheses:

(1) the video-based intervention groups will demonstrate lower rates of anxiety and loneliness than vignette and control groups, (2) the video-based group that presents an individual with COVID-19 will demonstrate lower rate of stigma than other groups.

Study Overview

Detailed Description

Currently, the world is experiencing a Coronavirus outbreak, COVID-19, which originated in mainland China in December 2019, spread rapidly to South Korea and Europe, Italy in particular, between January and March of 2020 and is currently spreading in all continents and has been recognized as a pandemic. It is of high importance to monitor how the trends in COVID-19 outbreak are shaping the social contexts and norms across communities and families. In a time in which individuals all over the world are experiencing quarantine, it is important to evaluate the potential surge of the phenomena of social anxiety, stigma, and of perceived fear and loneliness. Furthermore, it is critical to study interventions that aim to reduce each of these. The overall goal of this study is to evaluate the association of quarantine measures for COVID-19 and perceived anxiety, stigma and loneliness and to evaluate the efficacy of interventions in reducing anxiety, loneliness and perception of stigma induced by self-isolation during the outbreak. The hypotheses will be tested using ANOVA and multinomial logistic regressions. An alpha level of 0.01 will be used to account for multiple testing.

Study Type

Interventional

Enrollment (Actual)

1200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10025
        • Columbia University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • At least 18 years old
  • Younger than 70 years old
  • United States resident

Exclusion Criteria:

  • Less than 18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
No intervention
Placebo Comparator: Informational sheet (IS)
participant receives an informational sheet about COVID-19
An informational sheet to learn about the COVID-19 outbreak (standard).
Other Names:
  • Vignette
Active Comparator: IS + Video Solo
participants an informational sheet about COVID-19 and a 90 seconds video aimed at sensitizing participants to COVID-19 related stigma
An informational sheet to learn about the COVID-19 outbreak (standard).
Other Names:
  • Vignette
A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
Active Comparator: IS + Video Friends
participants an informational sheet about COVID-19 and a 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends.
An informational sheet to learn about the COVID-19 outbreak (standard).
Other Names:
  • Vignette
A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in total stigma score 2 weeks after the intervention
Time Frame: Baseline and 2 weeks

This is designed to measure stigma associated with COVID-19. A continuous variable will be obtained as a sum of questionnaire items ordinal answers (4 questions, score range 4-16, 4 = low stigma, 16 = high stigma) adapted from the HIV stigma validated questionnaire (HIV stigma scale, Berger et al., 2001).

  1. Strongly disagree = 1
  2. Disagree = 2
  3. Agree = 3
  4. Strongly agree = 4
  5. prefer not to answer: missing value
Baseline and 2 weeks
Change in total fear score 2 weeks after the intervention
Time Frame: Baseline and 2 weeks

This is designed to measure fear associated with COVID-19. A continuous variable will be obtained as a sum of questionnaire items (4 questions, score range 4-16, 4 = low fear, 16 = high fear) addressing fear of contracting COVID-19 and fear of consequences of COVID-19.

  1. Not at all = 1
  2. A bit = 2
  3. Quite a bit = 3
  4. A lot = 4

OR

  1. Strongly disagree = 1
  2. Disagree = 2
  3. Agree = 3
  4. Strongly agree = 4
  5. Prefer not to answer = missing value
Baseline and 2 weeks
Change in loneliness ordinal score 2 weeks after the intervention
Time Frame: Baseline and 2 weeks

Subjects will answer the following questionnaire item and an ordinal variable will be calculated (1 = low loneliness, 4 = high loneliness):

How lonely do you feel?

  1. Not at all = 1
  2. A bit = 2
  3. Quite a bit = 3
  4. A lot = 4
Baseline and 2 weeks
Change in fear of people COVID-19+ ordinal score 2 weeks after the intervention
Time Frame: Baseline and 2 weeks

Ordinal variable from the questionnaire item (1 = low fear of people, 4 = high fear of people):

How much are you afraid of people diagnosed with Coronavirus (COVID-19)?

  1. Not at all = 1
  2. A bit = 2
  3. Quite a bit = 3
  4. A lot = 4
Baseline and 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in time spent on internet ordinal score 2 weeks after the intervention
Time Frame: Baseline and 2 weeks

Ordinal variable from the questionnaire item time spent on the internet (for leisure or work-related activities) in the past week (averaged in number of hours)(1 = less time, 4 = more time):

  1. <1 h = 1
  2. 1h-4h = 2
  3. 4h-7h = 3
  4. >7h = 4
Baseline and 2 weeks
Change in social activity ordinal score 2 weeks after the intervention
Time Frame: Baseline and 2 weeks

Ordinal variable from the questionnaire item on social contact seeking behavior in the past week (How many times did you contact [in person or via video call] your friends/family members over the last week (1 = low social activity, 4 = high social activity)?

  1. 0-2 = 1
  2. 2-5 = 2
  3. 5-7 = 3
  4. more than 7 = 4
Baseline and 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Linda Valeri, PhD, Assistant Professor of Biostatistics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2020

Primary Completion (Actual)

April 16, 2020

Study Completion (Actual)

April 16, 2020

Study Registration Dates

First Submitted

January 29, 2021

First Submitted That Met QC Criteria

February 1, 2021

First Posted (Actual)

February 2, 2021

Study Record Updates

Last Update Posted (Actual)

February 2, 2021

Last Update Submitted That Met QC Criteria

February 1, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Informational sheet

3
Subscribe